Switching GLP-1 medications used to be rare. In 2026, it is routine — semaglutide-to-tirzepatide swaps, and the reverse, are among the most common requests at telehealth weight-loss programs.
The reasons boil down to three: plateaus, side effects, and price. But the switch itself is not plug-and-play. There is no official mg-to-mg conversion between the two drugs, no FDA switching protocol, and a billing calendar full of traps. Here is what the labels actually say, what prescribers typically do, and what a switch does to your monthly bill.
Why People Are Switching GLP-1 Medications
Reason 1: the plateau. In the STEP 1 trial published in the New England Journal of Medicine, semaglutide 2.4 mg averaged 14.9% body-weight loss over 68 weeks. The SURMOUNT-1 trial reported up to 20.9% at 72 weeks on tirzepatide’s highest dose. Those are different trials with different designs — not a head-to-head — but that gap is why people who stall on semaglutide ask about tirzepatide.
Reason 2: side effects. Nausea, vomiting, and diarrhea are the most common issues with GLP-1 drugs, per Cleveland Clinic. Tolerance is individual. Some people who struggle on one molecule do better on the other — in either direction.
Reason 3: price. At Ro, the Wegovy pen runs $199 to $399 a month by dose, while the Zepbound KwikPen runs $299 the first month, then $399 to $449. On the compounded side, the gap shrinks: bmiMD lists compounded semaglutide at $99/month and compounded tirzepatide at $139/month on 12-month plans. Sometimes the switch is not about the drug at all. It is about the bill.
Semaglutide vs Tirzepatide: What Actually Changes
These are different molecules, not different strengths of the same thing. Semaglutide is a GLP-1 receptor agonist — Cleveland Clinic explains these drugs slow stomach emptying and act on appetite signals. Tirzepatide hits the GLP-1 receptor plus a second one, GIP.
Here is the side-by-side:
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |
|---|---|---|
| FDA approval for weight management | June 2021 | November 2023 |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Label starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Maintenance dose | 2.4 mg | 5, 10, or 15 mg |
| Key trial result | 14.9% avg at 68 weeks (STEP 1) | Up to 20.9% at 72 weeks (SURMOUNT-1) |
Note the milligram scales. Wegovy tops out at 2.4 mg; Zepbound starts higher than that, at 2.5 mg, and climbs to 15 mg. The numbers mean nothing across drugs — 1 mg of semaglutide is not weaker than 2.5 mg of tirzepatide. Both molecules also exist as diabetes brands (Ozempic and Mounjaro); our guide to GLP-1 for diabetes vs weight loss explains how the labels differ.
The No-Conversion Rule: Why You Restart Low
Here is the fact that surprises most switchers: neither FDA label includes a switching protocol. The Wegovy prescribing information covers starting from zero. So does Zepbound’s. No dose-equivalence table between the two drugs exists in either document.
So prescribers improvise carefully. The most common approach reported in clinical practice is a clinician-guided restart: stop drug A, then start drug B at or near its label starting dose. For tirzepatide that means 2.5 mg weekly — just 17% of its top dose. For a reverse switch, it means restarting somewhere on the Wegovy ladder, often at 0.25 or 0.5 mg.
Some clinicians move a well-tolerated patient up the new ladder faster, or park them at a middle dose. That is a judgment call, not a published standard — which is exactly why switching GLP-1 medications on your own, with leftover pens or vials, is a bad idea. The full climb is mapped in our Zepbound dosage schedule guide: 2.5 mg for 4 weeks, then 5 mg, with 2.5 mg steps every 4-plus weeks after.
Washout Questions: How Long Between Drugs?
There is no FDA-mandated washout period between semaglutide and tirzepatide. But pharmacology sets some guardrails.
Semaglutide’s half-life is about 1 week, per the Wegovy prescribing information. That means roughly 50% of the drug is still circulating a week after your last shot, and meaningful levels persist for several weeks. The label itself hints at how slow the exit is: it tells patients to stop Wegovy at least 2 months before a planned pregnancy because of the long washout.
In practice, a common approach is to take the first dose of the new drug when the next weekly dose of the old one would have been due — a clean one-week handoff. Some prescribers stretch the gap if nausea or vomiting is still active. The one hard rule: never inject both drugs in the same week. You would be stacking two appetite-suppressing gut-slowing agents, and the FDA has flagged dosing errors as a real-world harm with these drugs. A stacked week is also burned money — a single month of medication runs $99 to $449 at most programs.
Ask your prescriber to set the exact handoff date. That is the entire washout plan, written down.
Which Direction Are You Switching?
The direction changes the math and the expectations.
Semaglutide to tirzepatide is usually a results play. You are moving toward the molecule with the bigger trial numbers — up to 20.9% in SURMOUNT-1 — and a higher bill at almost every program. Expect 4 to 8 weeks of re-titration at partial doses before the new drug shows its full hand.
Tirzepatide to semaglutide is usually a budget play. The savings are real: bmiMD’s 12-month plans price compounded semaglutide $40/month cheaper than tirzepatide ($99 vs $139) — about $480 a year. At TrimRx, promo pricing runs $199 for semaglutide vs $349 for tirzepatide. At Ro, dropping from the Zepbound KwikPen ($399-$449) to a Wegovy pen ($199-$399) can cut up to $250 a month at the entry dose.
Either direction, the same two rules hold: no mg-to-mg conversion, and a clinician picks your restart dose.
What Switching GLP-1 Medications Costs
Now the fine print — because the price of switching GLP-1 medications is mostly hiding in billing terms, not drug lists.
Here is the monthly gap between molecules at four compounded-medication programs. Reminder: compounded semaglutide and tirzepatide are not FDA-approved.
| Program | Compounded semaglutide | Compounded tirzepatide | Monthly swing |
|---|---|---|---|
| bmiMD | $99/mo (12-month plan) | $139/mo (12-month plan) | +$40 |
| Noom Med | $129 first month, then $249-$279/mo | $149 first month, then $299/mo | +$20 to +$50 |
| MEDVi | $179 first month, then $299/mo | From $349 first month; $399-$499 refills per third-party pricing reports | +$100 to +$200 |
| TrimRx | $199-$349/mo | $349-$449/mo | +$100 to +$150 |
On the brand-name path, Ro’s spread runs from a $199 entry-dose Wegovy pen to a $449 top-dose Zepbound KwikPen — before its $149/month membership. See where each program lands in our best tirzepatide programs ranking.
Three traps to check before you switch:
Prepaid plans bill upfront. bmiMD’s headline $99 and $139 rates require 12-month plans billed as $1,188 or $1,638 at once. Switch molecules mid-plan and you are negotiating with a refund policy, not a menu.
Refund windows are tiny. Hers refunds initial medication orders only if canceled within 48 hours, and shipped orders are non-refundable, per third-party pricing reports. MEDVi says refunds are generally not available once a cycle’s medication has been dispensed.
Quarterly billing lumps. Noom Med bills $537 to $837 per 12-week cycle after month one, depending on plan. Time your switch to the cycle boundary or eat the overlap.
Compounded Switches Carry Extra Fine Print
Plenty of switches happen entirely inside the compounded market — semaglutide at $99-$299 to tirzepatide at $139-$499. One thing does not change: compounded GLP-1s are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness, or quality.
For switchers, the sharpest risk is dose confusion. The FDA’s alert on unapproved GLP-1 drugs reports dosing errors with compounded products, including patients drawing several times the intended amount from multi-dose vials. Concentrations vary by pharmacy — so a switch can mean a new molecule, a new concentration, and a new syringe measurement all in the same week.
Protect yourself with two checks. Confirm the exact milligrams of your first dose with the prescriber, in writing. And confirm which compounding pharmacy fills it — programs that name their pharmacies make that possible; many do not.
How to Switch Without Losing Ground
A clean switch is a five-step process, and none of the steps is optional.
1. Name the reason. Plateau, side effects, or price. It decides direction, and whether a dose change on your current drug might solve it for $0.
2. Set the handoff date with your prescriber. Usually the day your next old-drug dose was due. Write down the new starting dose — likely 2.5 mg for tirzepatide or 0.25-0.5 mg for semaglutide.
3. Check the billing calendar first. Cancel timing matters when plans bill $1,188 upfront or in $537+ quarterly lumps. Cancellation is not a refund.
4. Expect a re-titration dip. You may spend 4 to 8 weeks below your old appetite control while the new drug climbs. Nausea can also return at each step — that is the pattern Cleveland Clinic describes for these drugs, not a sign the switch failed.
5. Judge at maintenance, not week 2. The trial numbers — 14.9% and up to 20.9% — came from 68 to 72 weeks at full protocol, not a first month at a starter dose.
Switching is a tool, not a reset button. Used with a clinician and a calculator, it can buy you better results or a smaller bill — sometimes both. To see every drug and program option in one place, start with our 10 best weight loss meds rundown.